re: rally rally rally rally
SciGen Limited ("SciGen") announced today that it will commence marketing and sales of Sci-8-VacTh4 its new 3"' generation mammalian cell-derived Hepatitis B vaccine in Hong Kong on 15 May 2003. This new Hepatitis B vaccine aims to control the spread of the Hepatitis E disease in Hong Kong, and thereby reduce its associated morbidity and mortality. Chronic Hepatitis B infection can cause liver cirrhosis and fiver cancer. Mr Mark Cornpton, Managing Director and CEO of SciGen said that "Sci-B-VacT" is the principal product in SciGen's portfolio and that the commencement of sales in Hung Kong is further evidence of SciGen's ability to roll products out across the Asia Pacific region". "We plan to host a medical symposium on Sci-8-Vac'" in Hung Kong as we have done in other countries where the vaccine has been launched in order to communicate to the medical community the beneficial properks of the vaccine and to raise SciGen's profile" Mr Cornpton said. A media and direct mail program to medical practitioners has already commenced. The incidence of Hepatitis B in t-iong Kong is high, at &-1O%. Prevention through vaccination is the only effective medical measure available to control its spread. Registrations of SciGen's other products such as recombinant human insulin are in train in a number of other countries in the region. Despite a lengthier process than expected within the Indian Ministry of Health in the registration of SciGen's insulin in India, the process is now well under way and expected to conclude in the middle of this year with sales expected to commence in early FY 04 which is later than originally anticipated. SciGen has also now submitted its registration dossier for Sci-B-Vac'" for approval in Australia, New Zealand and India. SciGen already generates sales from its recombinant human growth hormone (SciTropinT") and its third generation Hepatitis B vaccine (Sci-B-VacTh") in a number of countries in the Asia Pacific region using its own sales ancl marketing infrastructure. SciGen has offices and sales teams in Singapore, Australia, Philippines, Hong Kong, Korea and Vietnam with strategic partners in India, Indonesia, Poland, US and the Netherlands.
SIE Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
